Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin Chloride OROS in Korean Overactive Bladder Patients
NCT00613327Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of oxybutynin in overactive bladder (OAB), sponsored by Janssen Pharmaceutical. Started Sep 2007; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00613327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00613327.